Newomics Inc. Places Its 100th Mass Spectrometry Front-end System
Customers include 8 of the top 10 global biopharmaceutical companies, and leading institutions in academia and biotech
Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.
Additional stories:
Newomics M3 Emitter, September 30, 2021, ipo.lbl.gov
Newomics Closes $7.9 Million Series B Financing to Accelerate Growth, December 4, 2020, Newomics press release
Startup Newomics Enters Precision Medicine Market, January 2, 2018, ipo.lbl.gov
Screening for Disease of Toxins in a Drop of Blood, October 18, 2017, Berkeley Lab News Center.